Next 10 |
2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...
2024-06-21 15:00:42 ET More on the markets SPY: The Upside Is Likely Capped SPY: Rating Downgrade Due To Overvaluation Perfect Time For November Election Protection UBS says the current market conditions and the late 1990s have many differences Wolfe ...
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is one of today's top gainers. The company's shares have moved 30.16% on the day to $5.39. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatme...
2024-06-20 08:30:04 ET UBS analyst issues NEUTRAL recommendation for ZNTL on June 20, 2024 06:35AM ET. ZNTL was trading at $4.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 4 - Hold recommend...
A look at the top 10 most actives in the United States Reliance Global Group Inc. (RELI) rose 76.2% to $0.3911 on volume of 383,719,808 shares NLS Pharmaceutics Ltd. (NLSP) rose 82.1% to $0.2701 on volume of 302,290,803 shares NVIDIA Corporation (NVDA) rose 3.5% to $135.58 on volume of 28...
2024-06-18 15:00:05 ET Akash Tewari from Jefferies issued a price target of $6.00 for ZNTL on 2024-06-18 14:17:00. The adjusted price target was set to $6.00. At the time of the announcement, ZNTL was trading at $4.305. The overall price target consensus is at $32.33 wit...
2024-06-18 14:30:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for ZNTL on June 18, 2024 01:08PM ET. The previous analyst recommendation was Overweight. ZNTL was trading at $4.55 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-18 13:00:04 ET Bradley Canino from Stifel Nicolaus issued a price target of $10.00 for ZNTL on 2024-06-18 11:46:00. The adjusted price target was set to $10.00. At the time of the announcement, ZNTL was trading at $5.39. The overall price target consensus is at $...
2024-06-18 12:00:05 ET Robert Driscoll from Wedbush issued a price target of $4.00 for ZNTL on 2024-06-18 10:45:00. The adjusted price target was set to $4.00. At the time of the announcement, ZNTL was trading at $5.7. The overall price target consensus is at $40.67 with...
ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL) complied with federal securities laws. On June 18, 2024, Zentalis announced that “the ...
News, Short Squeeze, Breakout and More Instantly...
Zentalis Pharmaceuticals Inc. Company Name:
ZNTL Stock Symbol:
NASDAQ Market:
Zentalis Pharmaceuticals Inc. Website:
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is one of today's top gainers. The company's shares have moved 30.16% on the day to $5.39. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatme...
2024-06-20 08:30:04 ET UBS analyst issues NEUTRAL recommendation for ZNTL on June 20, 2024 06:35AM ET. ZNTL was trading at $4.14 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 4 - Hold recommend...
A look at the top 10 most actives in the United States Reliance Global Group Inc. (RELI) rose 76.2% to $0.3911 on volume of 383,719,808 shares NLS Pharmaceutics Ltd. (NLSP) rose 82.1% to $0.2701 on volume of 302,290,803 shares NVIDIA Corporation (NVDA) rose 3.5% to $135.58 on volume of 28...